Good morning, everyone, and welcome to the middle of the week. You made it this far, so why not carry on? Our survival plan calls for quaffing a cup or three of delicious stimulation — peppermint mocha is on our menu. As always, you are welcome to join us. Remember — no prescription is required. So time to get cracking. After all, meetings, phone calls, and deadlines are looming. To help you along, we have gathered the usual menu of tidbits. We hope you find them helpful. Meanwhile, have a wonderful day and do stay in touch …

A U.S. appeals court upheld a ruling that a crucial patent on Johnson & Johnson’s (JNJ) blockbuster Remicade arthritis treatment is invalid, because the concepts were covered in a prior J&J patent. The decision limits J&J’s ability to seek damages from Pfizer (PFE), which already launched a lower-cost biosimilar version of the drug, but recently filed a lawsuit claiming J&J illegally maneuvered insurers to stifle sales of its Inflectra medication.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy